November 12, 2020
Miami, FL- Robert Buchanan will present Ambulero at the U Innovation Concept
to Commercialization Series. To register, please visit:
June 4, 2020
Washington, DC- Ambulero, Inc will be attending BIO Digital from June 8-12, 2020. For more information, please see www.bio.org.
June 2, 2020
Boston, MA - Ambulero, Inc. Will be attending Digital RESI from June 8-10, 2020. For more information, please see www.resiconference.com.
April 23, 2020
Boston, MA - Ambulero, Inc. will be attending Digital RESI from April 29-30, 2020. For more information about the event and to learn more about the company, please see www.resiconference.com.
April 6, 2020
Miami, Florida - Ambulero, Inc. is pleased to announce the appointment of Dr. Bruce Patsner, M.D., J.D., M.B.A as its FDA regulatory advisor.
“I am delighted to see Bruce join our company as our FDA advisor. His deep expertise in many areas of interest will help guide efforts to bring our therapeutics forward to treat serious vascular diseases” said Robert L. Buchanan, co-founder and CEO of Ambulero.
January 17, 2020
Miami, Florida - Ambulero, Inc. is pleased to announce that Dr. Omaida C. Velazquez (Chief Medical Officer) will be attending the World Stem Cell Summit to be held January 21-24 at the Hyatt Regency in Miami, Florida.
January 10, 2020
Miami, Florida - Ambulero, Inc. is pleased to announce that Dr. Carlton Anderson (COO) and Randy Berholtz (Chairman of the Board) will be attending the J.P. Morgan Healthcare Conference in San Francisco, CA on January 13-16, 2020.
December 12, 2019
Miami, Florida - Ambulero, Inc., a pre-clinical stage regenerative medicines company using gene and cell therapy approaches to treat vascular disease, today announced the appointment of Dr. Greg, Landry, Professor of Surgery, Division of Vascular Surgery, School of Medicine, Oregon Health & Sciences University, as Chair of the Scientific Advisory Board.
Dr. Landry comes to Ambulero as head of OHSU’s division of vascular surgery with clinical expertise in upper arterial and venous disease, abdominal aortic aneurysms, cerebrovascular disease, hemodialysis access and renovascular and visceral arterial disease.
“I am delighted to have Greg chair our Scientific Advisory Board and to provide the company with advice and guidance in our clinical trial designs for treating vascular disease” said Robert L. Buchanan, co-founder and CEO of Ambulero.
Other members of the Scientific Advisory Board are to be announced.
November 1, 2019
Miami, Florida - Ambulero Inc., a pre-clinical stage regenerative medicines company focused on developing next-generation cell and gene therapies announced an exclusive licensing agreement with the University of Miami for intellectual property relating to the development and commercialization of cell and gene therapies for ischemic diseases.
Under the terms of the agreement, Ambulero is granted exclusive rights to gene and cell therapy technologies for introducing the cell adhesion molecule E-selectin into tissues damaged by vascular disease. University of Miami researchers have shown in relevant animal models that administration of the adhesion molecule can enhance blood flow and wound healing.
Pursuant to the terms of the exclusive license agreement, the University of Miami will become a shareholder in the company and will receive an upfront payment and certain clinical, regulatory, and sales milestone payments, as well as royalties on net sales of products covered by the license.